Frontiers in Immunology (Jul 2022)
Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy
- Midie Xu,
- Midie Xu,
- Midie Xu,
- Jinjia Chang,
- Jinjia Chang,
- Wenfeng Wang,
- Xin Wang,
- Xin Wang,
- Xin Wang,
- Xu Wang,
- Xu Wang,
- Xu Wang,
- Weiwei Weng,
- Weiwei Weng,
- Weiwei Weng,
- Cong Tan,
- Cong Tan,
- Cong Tan,
- Meng Zhang,
- Meng Zhang,
- Meng Zhang,
- Shujuan Ni,
- Shujuan Ni,
- Shujuan Ni,
- Lei Wang,
- Lei Wang,
- Lei Wang,
- Zhaohui Huang,
- Zhenzhong Deng,
- Wenhua Li,
- Wenhua Li,
- Dan Huang,
- Dan Huang,
- Dan Huang,
- Weiqi Sheng,
- Weiqi Sheng,
- Weiqi Sheng
Affiliations
- Midie Xu
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Midie Xu
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Midie Xu
- Institute of Pathology, Fudan University, Shanghai, China
- Jinjia Chang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Jinjia Chang
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Wenfeng Wang
- Shanghai Urological Cancer Institute, Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
- Xin Wang
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xin Wang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Xin Wang
- Institute of Pathology, Fudan University, Shanghai, China
- Xu Wang
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Xu Wang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Xu Wang
- Institute of Pathology, Fudan University, Shanghai, China
- Weiwei Weng
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Weiwei Weng
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Weiwei Weng
- Institute of Pathology, Fudan University, Shanghai, China
- Cong Tan
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Cong Tan
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Cong Tan
- Institute of Pathology, Fudan University, Shanghai, China
- Meng Zhang
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Meng Zhang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Meng Zhang
- Institute of Pathology, Fudan University, Shanghai, China
- Shujuan Ni
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Shujuan Ni
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Shujuan Ni
- Institute of Pathology, Fudan University, Shanghai, China
- Lei Wang
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Lei Wang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Lei Wang
- Institute of Pathology, Fudan University, Shanghai, China
- Zhaohui Huang
- Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, China
- Zhenzhong Deng
- Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
- Wenhua Li
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Wenhua Li
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
- Dan Huang
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Dan Huang
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Dan Huang
- Institute of Pathology, Fudan University, Shanghai, China
- Weiqi Sheng
- Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
- Weiqi Sheng
- Department of Oncology, Shanghai Medical college, Fudan University, Shanghai, China
- Weiqi Sheng
- Institute of Pathology, Fudan University, Shanghai, China
- DOI
- https://doi.org/10.3389/fimmu.2022.934083
- Journal volume & issue
-
Vol. 13
Abstract
Accurate immune molecular typing is pivotal for screening out patients with colon adenocarcinoma (COAD) who may benefit from immunotherapy and whose tumor microenvironment (TME) was needed for reprogramming to beneficial immune-mediated responses. However, little is known about the immune characteristic of COAD. Here, by calculating the enrichment score of immune characteristics in three online COAD datasets (TCGA-COAD, GSE39582, and GSE17538), we identified 17 prognostic-related immune characteristics that overlapped in at least two datasets. We determined that COADs could be stratified into three immune subtypes (IS1–IS3), based on consensus clustering of these 17 immune characteristics. Each of the three ISs was associated with distinct clinicopathological characteristics, genetic aberrations, tumor-infiltrating immune cell composition, immunophenotyping (immune “hot” and immune “cold”), and cytokine profiles, as well as different clinical outcomes and immunotherapy/therapeutic response. Patients with the IS1 tumor had high immune infiltration but immunosuppressive phenotype, IS3 tumor is an immune “hot” phenotype, whereas those with the IS2 tumor had an immune “cold” phenotype. We further verified the distinct immune phenotype of IS1 and IS3 by an in-house COAD cohort. We propose that the immune subtyping can be utilized to identify COAD patients who will be affected by the tumor immune microenvironment. Furthermore, the ISs may provide a guide for personalized cancer immunotherapy and for tumor prognosis.
Keywords
